Skip to search formSkip to main contentSkip to account menu

CKD 602

Known as: CKD-602, CKD602 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

belotecanbelotecan hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Anticancer effects of CKD-602 (Camtobell®) via G2/M phase arrest in oral squamous cell carcinoma cell lines
CKD-602 (7-[2-(N-isopropylamino) ethyl]-(20S)-camptothecin, belotecan) is a synthetic water-soluble camptothecin derivative and… 
2011
2011
Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models
Liposomes, such as pegylated-liposomal CKD-602 (S-CKD602), undergo catabolism by macrophages and dendritic cells (DCs) of the… 
2011
2011
A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
2010
2010
A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
2010
2010
The Efficacy and Toxicity of Belotecan (CKD-602), A Camptothecin Analogue Topoisomerase I Inhibitor, in Patients with Recurrent or Refractory Epithelial Ovarian Cancer
Abstract This study evaluated the efficacy and toxicity of belotecan (CKD-602), a new camptothecin analogue topoisomerase i… 
2009
2009
CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines.
CKD-602 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, belotecan) is a synthetic water-soluble camptothecin derivative and… 
2006
2006
Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
2013 Background: S-CKD602 is a pegylated STEALTH liposomal formulation of CKD-602, a semi-synthetic analogue of camptothecin (CPT… 
Review
2003
Review
2003
CKD-602. Chong Kun Dang.
Chong Kun Dang is developing the camptothecin analog CKD-602 for the potential treatment of cancer. By August 2000, phase II… 
2003
2003
Safety Pharmacology of CKD-602, a Novel Anticancer Agent
Summary CKD-602 ((20S)-7-[2-(N-isopropylamino)-ethyl]-camptothecin · HCl, CAS 213819-48-8) is a new class of anticancer drug that… 
Highly Cited
1998
Highly Cited
1998
Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor
We developed a novel water-soluble camptothecin analogue, CKD602, and evaluated the inhibition of topoisomerase I and the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)